Ameriprise
FATE icon

Ameriprise’s Fate Therapeutics FATE Stock Holding History

Ameriprise’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-261,671
Closed -$330K – 4117
2025
Q3 		$330K Sell
261,671
-78,043
-23% -$84.1K ﹤0.01% 3767
2025
Q2 		$380K Sell
339,714
-71,618
-17% -$83.2K ﹤0.01% 3619
2025
Q1 		$325K Buy
411,332
+234,171
+132% +$287K ﹤0.01% 3652
2024
Q4 		$292K Sell
177,161
-72,581
-29% -$183K ﹤0.01% 3732
2024
Q3 		$874K Buy
249,742
+7,310
+3% +$28.4K ﹤0.01% 3274
2024
Q2 		$795K Sell
242,432
-41,958
-15% -$184K ﹤0.01% 3247
2024
Q1 		$2.09M Buy
284,390
+32,741
+13% +$203K ﹤0.01% 2850
2023
Q4 		$941K Sell
251,649
-23,843
-9% -$56.3K ﹤0.01% 3210
2023
Q3 		$584K Buy
275,492
+27,394
+11% +$90.8K ﹤0.01% 3350
2023
Q2 		$1.18M Buy
248,098
+171,039
+222% +$944K ﹤0.01% 3100
2023
Q1 		$439K Buy
77,059
+58,233
+309% +$351K ﹤0.01% 3474
2022
Q4 		$190K Sell
18,826
-66,231
-78% -$1.24M ﹤0.01% 3718
2022
Q3 		$1.91M Buy
85,057
+5,183
+6% +$150K ﹤0.01% 2808
2022
Q2 		$1.98M Buy
79,874
+9,742
+14% +$269K ﹤0.01% 2813
2022
Q1 		$2.72M Sell
70,132
-441,520
-86% -$17.1M ﹤0.01% 2780
2021
Q4 		$29.9M Sell
511,652
-285,019
-36% -$16.2M 0.01% 1121
2021
Q3 		$47.2M Buy
796,671
+128,223
+19% +$10.1M 0.02% 792
2021
Q2 		$58M Buy
668,448
+46,743
+8% +$3.77M 0.02% 733
2021
Q1 		$51.3M Buy
621,705
+357,066
+135% +$34.2M 0.02% 760
2020
Q4 		$24.1M Sell
264,639
-74,186
-22% -$4.61M 0.01% 1102
2020
Q3 		$13.5M Sell
338,825
-15,233
-4% -$532K 0.01% 1339
2020
Q2 		$12.1M Sell
354,058
-150,968
-30% -$4.5M 0.01% 1386
2020
Q1 		$11.2M Sell
505,026
-1,445,247
-74% -$36.5M 0.01% 1310
2019
Q4 		$38.2M Buy
1,950,273
+447,711
+30% +$7.11M 0.02% 819
2019
Q3 		$23.3M Buy
1,502,562
+799,286
+114% +$15.3M 0.01% 1030
2019
Q2 		$14.3M Buy
+703,276
New +$12.7M 0.01% 1438
2018
Q2 		– Sell
-88,364
Closed -$862K – 3658
2018
Q1 		$862K Buy
+88,364
New +$847K ﹤0.01% 3037

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ameriprise's FATE Position: Q4 2025 in Review

Ameriprise sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 261,671 shares — an estimated $330K sold.

Ameriprise first reported a position in FATE in Q1 2018 and held it in 27 quarters. The position peaked at $58M in Q2 2021. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Ameriprise reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 261,671 Fate Therapeutics shares in Q4 2025, an estimated $330K.
  • Ameriprise first reported a position in Fate Therapeutics in Q1 2018 and held it in 27 quarters.
  • Ameriprise's Fate Therapeutics position peaked at $58M in Q2 2021.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.